Phase 1, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of ALN-APOC3 in Adult Participants with Dyslipidemia

ALN-APOC3 - Regeneron

https://cattendee.abstractsonline.com/meeting/21541/presentation/8194

Janaki Vekaria, Hisham Abdallah, Regeneron Pharmaceuticals, Tarrytown, NY; Judith Meadows, Regeneron Pharmceuticals, Tarrytown, NY; Susan Rhee, Giulia Redaelli, Manish Ponda, Robert Pordy, Regeneron Pharmaceuticals, Tarrytown, NY

Sep 5, 2026